ArticleAmerican journal of ophthalmology case reports2025
Surgical management of two cases with macular exudation from retinal macroaneurysms refractory to focal photocoagulation.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report two cases of macular exudations resulting from retinal arterial macroaneurysms (MaAs) refractory to focal photocoagulations that were treated with a new surgical technique including subretinal balanced saline solution (BSS) injection to dilute lipid-rich subretinal fluid (SRF) and facilitate absorption of the SRF, intentional retinal hole formation to direct SRF into the vitreous cavity, and laser photocoagulation posterior to the MaAs to prevent intraretinal fluid and SRF from reaching the fovea. Observations: A 70-year-old man with macular edema (ME) refractory to anti-vascular endothelial growth factor (VEGF) therapy was referred to our hospital. Fundus examination showed retinal arterial MaAs and hard exudations. He underwent laser photocoagulation, sub-Tenon injections of triamcinolone acetonide (STTA), and anti-VEGF therapies; the ME recured despite all treatments. Subretinal lipid-rich exudatoins from retinal arterial MaAs involved the macula, which led to severe vision loss. Therefore, vitrectomy with the new technique was planned to flush out the lipid-rich SRF and prevent new exudations from reaching the macula. Postoperatively, the SRF resolved completely and the ME has not reccured until 59 months postoperatively at his latest visit. The second patient was a 77-year-old woman with an epiretinal membrane and ME with sarcoidosis. She underwent anti-VEGF therapy, STTA injection, and focal laser photocoagulation. The vision-threatening ME persisted. She underwent vitrectomy with the new technique, and the macular exudation resolved promptly. The ME has not recurred 27 months postoperatively. Conclusions: Vitrectomy with this technique may be considered in cases with vision-threatening ME due to retinal MaAs resistant to combined multiple conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.